Rarecells, Inc. Announces Breakthrough Publication on Circulating Giant Cancer Cells Detected in Patients with MDS

Rarecells, Inc. has made an exciting announcement about a major breakthrough in the detection of Circulating Giant Cancer Cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS). &nbsp In collaboration with Dr. Azra Raza from Columbia University Irving Medical Center, Rarecells has conducted groundbreaking research that has revealed the presence of CGCCs in MDS patients for the first time ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 21.
  • textsms

Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, has recently announced the publication of data from its successful Phase 1 clinical trial evaluating Annamycin as a single agent treatment for relapsed or refractory Acute Myeloid Leukemia (AML). The findings of this study were published in the highly regarded British Journal of Cancer Research, after undergoing a thorough peer-re..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 14.
  • textsms